1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

EYPT
EyePoint Pharmaceuticals, Inc.US flagNASDAQ Global Market
4.58
USD
+0.02
- -
383.99MMarket Cap
EyePoint Pharmaceuticals, Inc.
EYPT
(NASDAQ Global Market)

Recent

price

4.58

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
12.53
2.55
1.7
0.93
1.27
9.04
0.51
2.13
0.64
1.95
2.68
1.28
1.11
1.18
0.77
0.43
0.03
Revenue per Share
4.76
-4.43
-11.95
-5.16
-4.87
2.16
-6.81
-5.23
-11.5
-5.44
-3.54
-2.03
-2.74
-1.82
-2.32
-3.17
-3.77
Basic EPS, GAAP
5.37
-1.69
-4.52
-3.82
-3.98
3.45
-5.2
-5.84
-4.76
-5.46
-1.15
-1.75
-1.8
-0.04
-2.31
-3.32
-3.33
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
17.83
18.04
6.55
3.31
5.09
7.94
6.11
3.39
1.57
0.76
1.02
5.44
2.83
5.43
4.93
3.7
1.96
Book Value per Share
4.95
7.65
4.52
1.83
4.15
7.29
5.79
3.3
-2.64
-1.77
-0.37
4.77
2.83
5.43
4.93
3.7
1.96
Tangible Book Value per Share
2
2
2
2
3
3
3
4
5
10
13
29
37
39
56
73
81
Basic Weighted Avg Shares
23
5
4
2
3
27
2
8
3
20
34
37
41
46
43
31
3
Sales/Revenue/Turnover
39.44
-201.47
-294.41
-561.41
-390.67
24.17
-1,344.07
-246.4
-887.34
-235.02
-108.28
-149.64
-190.65
-163.13
-337.06
-775.98
-11,365.22
Operating Margin (%)
3
3
2
1
1
1
1
1
1
3
3
3
2
- -
2
2
3
Depreciation Expense
9
-9
-25
-12
-13
6
-22
-18
-53
-57
-45
-58
-102
-71
-131
-232
-307
Net Income, GAAP
0.26
- -
- -
- -
- -
1.49
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
37.97
-173.78
-704.34
-555.3
-384.54
23.89
-1,330.06
-245.19
-1,795.71
-278.88
-131.82
-158.14
-246.97
-153.84
-302.43
-739.42
-10,994.73
Profit Margin (%)
16
20
13
9
17
26
25
12
18
30
48
214
138
282
334
292
147
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
17
50
40
38
35
5
22
21
20
LT Debt
33
37
14
8
15
23
21
13
12
8
19
184
96
266
337
306
166
Total Equity
32.05
- -
- -
- -
- -
33.04
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
30.94
- -
- -
- -
- -
33.15
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
30.94
-24.49
-97.26
-111.55
-118.06
33.15
-97.39
-108.05
-424.98
-567.45
-337.87
-57.58
-72.84
-39.04
-43.42
-72.19
-148.7
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
21
20
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
83
83
85
Market Capitalization
1,513
1,076
1,215

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
329
250
189
Cash, Cash Equivalents & STI
306
223
180
Accounts Receivable, Net
1
1
- -
Inventories
2
1
2
Total Current Liabilities
37
37
42
Payables & Accruals
- -
- -
29
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
107.51%
208.08%
-9.03%
Free Cash Flow
811.9%
1,652.87%
86.82%
Net Income, GAAP
-4.42%
47.01%
77.25%
Sales/Revenue/Turnover
86.47%
-0.59%
-27.5%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12
9
11
12
43
2025
24
5
1
1
31
2026
1
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.55
-0.58
-0.54
-0.64
-2.32
2025
-0.65
-0.85
-0.85
-0.81
-3.17
2026
-0.99
-1.09
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Valneva SE (VLAP.PA)
Shattuck Labs, Inc. (STTK)
Aeterna Zentaris Inc. (AEZS)
Geron Corporation (GERN)
iBio, Inc. (IBIO)
Atai Beckley Inc. (ATAI)
Business
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) develops and commercializes innovative therapeutics for serious retinal diseases using its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery; its lead product candidate DURAVYU (EYP-1901) combines vorolanib, a selective tyrosine kinase inhibitor, for VEGF-mediated conditions including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), with prior Durasert formulations supporting four FDA-approved products administered to thousands of patients. Founded in 1987 and headquartered in Watertown, Massachusetts, with a manufacturing facility in Northbridge, Massachusetts, the clinical-stage biopharmaceutical company targets ophthalmology markets in the US and globally through Phase 3 pivotal trials. Recently, EyePoint completed enrollment in the Phase 3 LUGANO and LUCIA trials for DURAVYU in wet AMD involving over 900 patients, with topline data from LUGANO expected mid-2026; initiated the pivotal Phase 3 DME program with COMO and CAPRI trials following FDA alignment on a non-inferiority pathway, first dosing anticipated Q1 2026; presented preclinical data at AAO 2025 showing DURAVYU reduces IL-6 mediated inflammation by over 50% via JAK-1 inhibition alongside VEGF blockade; and raised $172.5 million in an oversubscribed October 2025 public offering to fund the DME program and extend cash runway into Q4 2027.

Company News

Company News APIChatGPT

  • globenewswire.com

    EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm

  • gurufocus.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

  • globenewswire.com

    EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals

  • globenewswire.com

    EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm

  • 247wallst.com

    Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, GitLab, GLOBAL FOUNDRIES, Martin Marietta Materials, Rocket Lab USA, Strategy, Toast, Tower Semiconductor, and More

  • globenewswire.com

    EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting

  • gurufocus.com

    EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

  • businesswire.com

    EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

  • prnewswire.com

    EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm

  • gurufocus.com

    EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law

  • businesswire.com

    EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

  • globenewswire.com

    Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm

  • globenewswire.com

    EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

  • businesswire.com

    NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm

  • gurufocus.com

    EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky

  • prnewswire.com

    EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT